Literature DB >> 7531518

Sequential order of T and B cell epitopes affects immunogenicity but not antibody recognition of the B cell epitope.

G Denton1, F Hudecz, J Kajtár, A Murray, S J Tendler, M R Price.   

Abstract

Synthetic peptide constructs, co-linearly linking a MUC1 mucin B cell epitope peptide to a known murine T cell epitope, both in T-B and B-T orientations, show that induction of high murine anti-MUC1 antibody titers is dependent on the presence and orientation of the T cell determinant. However, the sequential order of the epitopes does not affect binding of anti-B cell epitope antibodies to the constructs. Haplotype mismatching leads to a significant lowering of the anti-MUC1 antibody responses, implicating a central role for the T cell epitope in eliciting anti-B cell epitope responses. Secondary structure analysis by circular dichroism spectroscopy reveals the T-B construct to be partially ordered, while the B-T peptide adopts a highly ordered conformation in trifluoroethanol. These studies suggest that the sequential order of epitopes may significantly alter the immunogenicity of the peptide but may not necessarily affect its antigenicity. Immunogenicity of the peptide constructs may be governed by subtle differences in secondary structure, leading to variation in the way peptides are presented or processed within cells governing immune responses. These findings have relevance for the construction of peptides to be utilized as potential synthetic vaccines and for the design of peptide immunogens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7531518

Source DB:  PubMed          Journal:  Pept Res        ISSN: 1040-5704


  3 in total

1.  Immune Responses to the MUC1 Mucin.

Authors:  Graeme Denton; Michael R Price
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

2.  Enhanced immunogenicity of a functional enzyme by T cell epitope modification.

Authors:  Jeanette M Mucha; Marcia M Stickler; A J Poulose; Grant Ganshaw; Mae Saldajeno; Kathy Collier; Manley T Huang; Fiona A Harding
Journal:  BMC Immunol       Date:  2002-01-25       Impact factor: 3.615

3.  A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron.

Authors:  Iam Palatnik-de-Sousa; Zachary S Wallace; Stephany Christiny Cavalcante; Maria Paula Fonseca Ribeiro; João Antônio Barbosa Martins Silva; Rafael Ciro Cavalcante; Richard H Scheuermann; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.